Frontiers in Pharmacology 2026

6 papers
In 2026, research in Frontiers in Pharmacology focused on advanced evidence synthesis and precision drug delivery systems. A primary focus involved Bayesian Network Meta-Analysis and probabilistic ranking to determine comparative clinical effectiveness, especially for treatments lacking head-to-head clinical trials. This methodology was applied to evaluate pharmacological interventions for abdominal aortic aneurysm growth and the combination of traditional Chinese prescriptions with metformin for type 2 diabetes. These efforts aimed to standardize effect sizes for cross-study synthesis and address confounding by indication in observational healthcare data. Experimental studies during this period investigated stimuli-responsive nanocarriers, including hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin. Molecular research explored epitranscriptomic switches for mRNA stability and the role of the NSUN2–DHODH axis in reversing ferroptosis and oxaliplatin resistance in colorectal cancer. Contributions from authors such as Andrew S. Mikhail, Dieter Haemmerich, and John W. Karanian highlighted trends in longitudinal safety evaluations and the development of therapies for diseases without current approved treatments.

Top Research Directions

The 19 research directions with Frontiers in Pharmacology 2026 papers, ranked by paper count, next to 2025. Share is the fraction of the edition’s papers in the direction.

#Direction20262025Share 2026Share 20252025 rank
1Bayesian Network Meta-Analysis for Indirect Treatment Comparisons2033.3%0.0%—
2Probabilistic Treatment Ranking with Cumulative Ranking Curves2233.3%1.8%75
3Achieving Base-Level Resolution in Epitranscriptomics1016.7%0.0%—
4Cellular Neighborhood Topology in the Tumor Microenvironment1016.7%0.0%—
5Confounding by Indication in Observational Health Studies1116.7%0.9%109
6Epitranscriptomic Modulation of Transcript Half-Life1016.7%0.0%—
7Harmonizing Heterogeneous Protocols in Neuroimaging Research1016.7%0.0%—
8Mechanisms of the Clinical Implementation Gap1116.7%0.9%182
9Overcoming Short-Term Follow-Up Bias in Clinical Studies1116.7%0.9%216
10Overcoming Systemic Toxicity through Stimuli Responsive Targeted Delivery1016.7%0.0%—
11Pharmacological Interventions for the Fatty Liver Disease Treatment Gap1416.7%3.6%19
12Quantifying Relative Drug Efficacy Without Head-to-Head Trials1216.7%1.8%77
13Replicating Native Tissue Microenvironments in Cancer Models1016.7%0.0%—
14Separation of Function Mutagenesis in Multifunctional Proteins1016.7%0.0%—
15Spatial Transcriptomic Mapping and Cell Type Deconvolution1016.7%0.0%—
16Standardized Mean Differences for Heterogeneous Data Integration1016.7%0.0%—
17Temperature Responsive Matrices for Controlled Payload Delivery1016.7%0.0%—
18The Mechanics of Synergistic Combination Therapies1016.7%0.0%—
19Translating Genetic Target Validation into Small Molecule Inhibitors1016.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Frontiers in Pharmacology 2026 papers: a paper credits every institution named in its affiliations, once. 30 institutions share 6 credited papers.

#InstitutionPapersShare20252025 rank
1Capital Medical University 233.3%326
200ka6rp58 116.7%0—
30144s0951 116.7%0—
401s5dt366 116.7%0—
501x9zv505 116.7%0—
604wwgp209 116.7%0—
705qz7n275 116.7%0—
8Chengdu University of Traditional Chinese Medicine 116.7%71
9Chinese Academy of Sciences 116.7%73
10Gachon University 116.7%1302
11Hangzhou Institute of Medicine, Chinese Academy of Sciences 116.7%0—
12Heilongjiang University 116.7%0—
13Medical University of South Carolina 116.7%0—
14National Cancer Institute 116.7%0—
15National Institutes of Health 116.7%256
16North Sichuan Medical University 116.7%294
17Shandong University 116.7%261
18Shanghai Jiao Tong University 116.7%66
19Tel Aviv Sourasky Medical Center 116.7%0—
20Tufts University 116.7%1401
21Uniformed Services University of the Health Sciences 116.7%0—
22University of Auckland 116.7%0—
23University of Florida 116.7%270
24University of Leicester 116.7%0—
25University of Mauritius 116.7%0—
26University of Missouri–Kansas City 116.7%0—
27University of North Carolina at Greensboro 116.7%1340
28Wuhan University 116.7%0—
29Zhejiang Chinese Medical University 116.7%286
30Zhejiang University 116.7%413

Download all institutions as CSV

About this data

Papers. Frontiers in Pharmacology 2026 lists 6 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2025 use shares, since the edition went from 112 to 6 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 6 of 6 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Frontiers in Pharmacology 2026”, https://lacuna.tiptreesystems.com/venue/frontiers-in-pharmacology/2026.

Top Authors

AuthorPapers
Ji Wu1
Qian Zang1
Shikhar Shrestha1
Yueqin Cai1

Papers

Title
Beyond glycemic control: SGLT2 inhibitors as time-sensitive organ-protective agents in acute injury—mechanistic insights and translational implications
Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis
Editorial: Using behavioral theories to improve medication use
Efficacy and safety of traditional Chinese classic prescriptions combined with metformin in the treatment of type 2 diabetes mellitus: a Bayesian network meta-analysis
Hyperthermia-targeted rectal delivery of thermosensitive liposomal doxorubicin via intra-arterial and intravenous administration
Targeting the NSUN2–DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer